Prohost Biotech - Exclusive Biotech Research - A Comprehensive Resource for Biotech News

Promising Stocks in the First Two Trading Days of 2023

January 4, 2023 0

The Stock Market in the New Year It is still too early to tell how the …

Gilead Sciences – Still Way Undervalued

December 29, 2022 0

Prohost Letter #453 Gilead Sciences Still Way UNDERVALUED Finally, many analysts who happened to downgrade Gilead …

Why Kala Pharmaceuticals Stock is Soaring

December 28, 2022 0

Kala Pharmaceuticals Kala Pharmaceuticals (KALA) announced today that the U.S. FDA has accepted the investigational new drug …

A Note To Our Followers

December 23, 2022 2

Dear Friends and Followers, We confirm our optimism towards the future biotech firms that we selected …

Madrigal Pharmaceuticals and Akero Therapeutics: After Having No Treatment for NASH, We Now Have Two Products Expected to be Approved

December 19, 2022 0

Treatments for NASH Madrigal Pharmaceuticals (MDGL) is the second company after Akero Therapeutics (AKRO) to . …

What We Learned This Morning

December 13, 2022 0

Dear Subscribers, This is what we learned this morning: FTX: we learned about the arrest of …

Why IVERIC bio Rallied Today

November 18, 2022 0

IVERIC bio's Rally IVERIC Bio (ISEE) announced that the U.S. (FDA) has granted Breakthrough Therapy designation for …

Reata Pharmaceuticals Announces 3Q 2022 Financial Results and an Update on Clinical Development Programs

November 9, 2022 0

Reata Pharmaceuticals Announcements The FDA decision not to hold an Advisory Committee Meeting to discuss Reata …

Searching for Biotech Firms with Novel Drugs That Reached Clinical-Stage or Were Granted Early Fast Track Designation

October 28, 2022 0

Searching for Biotech Firms The search is for firms biotech firms that have reached clinical stage …

Acumen Pharmaceuticals: New Effort to Treat Alzheimer’s Disease Granted FDA Fast Track Designation

October 25, 2022 0

Acumen Pharmaceuticals Product ACU193 On October 23, 2022, Acumen Pharmaceuticals (ABOS) announced that the first clinical-stage …

Gilead and MacroGenics Announce Oncology Collaboration to Develop Promising Bispecific Antibodies

October 17, 2022 0

Gilead Sciences and MacroGenics Collaboration Announcement Gilead Sciences (GILD) and MacroGenics (MGNX) announced an exclusive option …

Reata Pharmaceuticals: Good News for the Prohost Pick

October 14, 2022 0

Reata Pharmaceuticals Announcement Regarding the NDA for Omaveloxolone for Friedreich’s Ataxia Reata Pharmaceuticals (RETA) announced that …

Travere Therapeutics: Treating IgA Nephropathy and Focal Segmental Glomerulosclerosis

October 14, 2022 0

IgA Nephropathy Searching for companies focused on treating severe diseases that have yet to find approved …

Treating Untreatable Disease – NASH

October 13, 2022 0

Prohost Letter #452 Treating Untreatable Disease - NASH Non Alcoholic Steatohepatitis The efforts spent on treating …

Amylyx Pharmaceuticals Announces FDA Approval of RELYVRIO™ for of ALS Leading to a Weird Stock Market Reception

September 30, 2022 0

Amylyx Pharmaceuticals in the NEWS Amylyx Pharmaceuticals (AMLX) announced that the U.S. FDA has approved RELYVRIO™ …

From Biogen and Eisai: Lecanemab Confirmatory Phase 3 Clarity Met Primary Endpoint for Early Alzheimer’s Disease

September 28, 2022 0

Biogen & Eisai Co and Early Alzheimer's Disease From Tokyo and Cambridge, Eisai Co., Ltd. and …

From bluebird bio: FDA Accelerated Approval for SKYSONA® Gene Therapy for Early, Active Cerebral Adrenoleukodystrophy

September 19, 2022 0

FDA Approves bluebird bio Product Skysona for Early, Active CALD SKYSONA is the first FDA approved …

Intellia Therapeutics: Excellent News from NTLA-2001 Phase 1 Clinical Trial

September 16, 2022 0

Intellia Therapeutics Intellia Therapeutics.(NTLA) and Regeneron Pharmaceuticals (REGN) today announced positive interim results from an ongoing Phase 1 …

Rhythm Pharmaceuticals & Akero Therapeutics: On the Morning of September 15, 2022

September 15, 2022 0

Rhythm Pharmaceuticals Rhythm Pharmaceuticals (RYTM): After soaring, based on great scientific and drug performance in treating …

Akero Therapeutics: Efruxifermin Met Primary Endpoint for Both Dose Groups in NASH Patients

September 13, 2022 0

Akero Therapeutics Akero Therapeutics (AKRO) - a clinical-stage company, today released topline data from HARMONY, a …

Exclusive Market Insight

& Scientific analysis

Latest Articlesddd

Promising Stocks in the First Two Trading Days of 2023

Gilead Sciences – Still Way Undervalued

Why Kala Pharmaceuticals Stock is Soaring

A Note To Our Followers

Madrigal Pharmaceuticals and Akero Therapeutics: After Having No Treatment for NASH, We Now Have Two Products Expected to be Approved

What We Learned This Morning

Why IVERIC bio Rallied Today

Reata Pharmaceuticals Announces 3Q 2022 Financial Results and an Update on Clinical Development Programs

Searching for Biotech Firms with Novel Drugs That Reached Clinical-Stage or Were Granted Early Fast Track Designation

Acumen Pharmaceuticals: New Effort to Treat Alzheimer’s Disease Granted FDA Fast Track Designation

Gilead and MacroGenics Announce Oncology Collaboration to Develop Promising Bispecific Antibodies

Reata Pharmaceuticals: Good News for the Prohost Pick

Travere Therapeutics: Treating IgA Nephropathy and Focal Segmental Glomerulosclerosis

Treating Untreatable Disease – NASH

Amylyx Pharmaceuticals Announces FDA Approval of RELYVRIO™ for of ALS Leading to a Weird Stock Market Reception

From Biogen and Eisai: Lecanemab Confirmatory Phase 3 Clarity Met Primary Endpoint for Early Alzheimer’s Disease

From bluebird bio: FDA Accelerated Approval for SKYSONA® Gene Therapy for Early, Active Cerebral Adrenoleukodystrophy

Intellia Therapeutics: Excellent News from NTLA-2001 Phase 1 Clinical Trial

Rhythm Pharmaceuticals & Akero Therapeutics: On the Morning of September 15, 2022

Akero Therapeutics: Efruxifermin Met Primary Endpoint for Both Dose Groups in NASH Patients